I am an accomplished healthcare marketing professional with extensive experience in developing strategies and implementing programs for successful pharmaceutical, biotech, and device brands and for both healthcare professional and patient audiences. I have developed and launched brands with large West Coast pharmaceutical/biotech manufacturers (Allergan, Amgen, Genentech), as well as start-ups such as CV Therapeutics and InterMune, and most recently, Atara and Myovant.My strategic leadership has been demonstrated in the oversight of multiple product launches and brand life cycle management opportunities in oncology, hematology/oncology, ophthalmology, neurology, diabetes, women’s health, and rare disease.Prior to my current role of VP, Account Director at Fishawack Healtho VP, Management Supervisor at Evoke Giant: Oversaw a business unit of approximately $8MM-$10MM in annual billings - Led two new business pitches resulting in the acquisition of two agency of record (AOR) clients, both with product candidates in pre-launch phase (one a T-cell immunotherapy, the other a women’s health oral treatment) o DDB Health San Francisco: Oversaw the development and implementation of the Aimovig® global pre-launch strategy and campaign - Required global alignment between co-promotion stakeholders in multiple regions for both Amgen and Novartis - Launched the first campaign to “own” the anti-CGRP migraine disease education territory ahead of multiple competitorso Digitas Health Lifebrands: Managed a portfolio of west coast clients, including Omeros’ Omidria for cataract surgeryo McCann RCW Healthcare: Over the course of ten years and based remotely in the Bay Area, started as Account Supervisor and was promoted twice, up to VP, Account Group Supervisor - Led the strategic brand development process for Blincyto® (Amgen), including content creation for the disease awareness campaign - Over the course of five years, helped to condition the ITP market, launch, build, and grow the Nplate® (Amgen) brand in the US, EU, and Canada - Successfully implemented the launch of Allergan’s Optive®, an OTC drop for dry eye - Oversaw the launch of Herceptin’s early stage (adjunctive) indication for HER2+ breast cancer with Genentech